Abstract
The majority of patients with Graves’ disease (GD) have some degree of ocular involvement and this requires surgical or medical intervention in about 5% of cases. There are autoimmune and inflammatory processes operating in Graves’ ophthalmopathy (GO), which together induce glycosaminoglycan production, edema and adipogenesis resulting in an increase in the volume of the orbital contents. GO is a heterogeneous disorder, i.e.: 1) whilst usually associated with hyperthyroidism it may occur in euthyroid (and even hypothyroid) patients; 2) expansion of orbital tissues may be due to ‘big-fat’ or ‘big muscles’. The heterogeneity is further exemplified by the spectrum of protocols which have succeeded in inducing aspects of the disease both in animal models and in humans including: 1) Production of severe hypothyroidism in guinea pigs by thyroidectomy and administration of pituitary extract (TSH); 2) Induction of T cells autoreactive to the thyrotropin receptor (TSHR) in mice; 3) Depletion of regulatory T cells in humans susceptible to autoimmunity; 4) Modulation of adipose tissue metabolism in mice and men. In addition, identical induction protocols result in different pathological features depending on the environment, e.g. TSHR primed T cells produce thyroiditis and ocular pathology in BALBc mice in Brussels but thyroid stimulating antibodies accompanied by elevated thyroxine in these animals (from the same supplier) in Cardiff. Thus, experiences in the induction of GO have confirmed the polygenic, multifactorial nature of the disorder and highlight the importance of careful disease classification to promote further progress in understanding.
Similar content being viewed by others
References
Weetman AP, McGregor AM. Autoimmune thyroid disease; further developments in our Understanding. Endocr Rev 1994, 15: 788–830.
Ludgate M, Baker GR. Unlocking the immunological mechanisms of orbital inflammation in thyroid eye disease. Clin Exp Immunol 2002, 127: 193–8.
Rees Smith B, Mclachlan S, Furmaniak J. autoantibodies to the thyrotropin receptor. Endocr Revs 1998, 9: 106–20.
Paschke R, Ludgate M. The thyrotropin receptor in thyroid disease. N Engl J Med 1997, 337: 1675–81.
Khoo DHC, Ho SC, Seah LL, et al. The combination of absent thyroid peroxidase antibodies and high thyroid stimulating immunoglobulins identifies a group at markedly increased risk of ophthalmopathy. Thyroid 1999, 9: 1175–80.
Crisp M, Lane C, Halliwell M, Wynford-Thomas D, Ludgate M. Thyrotropin receptor transcripts in human adult adipose tissue. J Clin Endocrinol Metab 1997, 82: 2003–5.
Bahn R, Dutton C, Natt N, Joba W, Spitweg C, Heufelder A. Thyrotropin receptor expression in Graves’ orbital adipose/connective tissues; potential autoantigen in Graves’ Ophthalmopathy. J Clin Endocrinol Metab 1998, 83: 998–1002.
Crisp MS, Starkey KJ, Lane C, Ham J, Ludgate M. Adipogenesis in thyroid eye disease. Invest Ophthalmol Vis Sci 2000, 41: 3249–55.
Menendez C, Baldelli R, Camina J P, et al. TSH stimulates leptin secretion by a direct effect on adipocytes. J Endocrinol 2003 Jan 176: 7–12.
Lavard L, Sehested A, Jacobsen BB, et al. Long term follow-up of an infant with thyrotoxicosis due to germline mutation of the TSH receptor gene (Met453Thr). Horm Res 1999, 51: 43–6.
Smelser GK. Experimental production of exophthalmos resembling that found in Graves’ disease. Proc Soc Exp Biol Med 1936, 35: 128–30.
Costagliola S, Many MC, Stalmans Falys M, et al. Transfer of thyroiditis, with syngeneic spleen-cells sensitized with the human thyrotropin receptor, to naive BALB/c and nod mice. Endocrinology 1996, 137: 4637–43.
Many MC, Costagliola S, Detrait M, Denef JF, Vassart G, Ludgate M. Development of an animal model of autoimmune thyroid eye disease. J Immunol 1999, 162: 4966–74.
Costagliola S, Many MC, Denef JF, Pohlenz J, Refetoff S, Vassart G. Genetic immunisation of outbred mice with thyrotropin receptor cDNA provides a model of Graves’ disease. J Clin Invest 2000, 105: 803–11.
Coles AJ, Wing N, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999, 354: 1691–5.
Smith TJ, Parikh SJ. HMC-1 mast cells activate human orbital fibroblasts in coculture: Evidence for up-regulation of prostaglandin E2 and Hyaluronan synthesis. Endocrinology 1999, 140: 3518–25.
Hufnagel TJ, Hickey WF, Cobbs WH, et al. Immunohistochemical and ultrastructural studies on the exenterated orbital tissues of a patient with Graves’ disease. Ophthalmology 1984, 91: 1411–9.
Sato A, Takemura Y, Yamada T, et al. A possible role of immunoglobulin E in patients with hyperthyroid Graves’ disease. J Clin Endocrinol Metab 1999, 84: 3602–5.
Yamada T, Sato A, Aizawa T, et al. An elevation of stem cell factor in patients with hyperthyroid Graves’ disease. Thyroid 1998, 8: 499–504.
Metcalfe R, Jordan N, Watson P, et al. Demonstration of IgG, IgA and IgE autoantibodies to the human thyrotropin receptor using flow cytometry. J Clin Endocrinol Metab 2002, 87: 1754–61.
Endo T, Ohta K, Haraguchi K, Onaya T. Cloning and functional expression of a thyrotropin receptor cDNA from rat fat-cells. J Biol Chem 1995, 270: 10833–7.
Roselli-Rehfuss L, Robbins LS, Cone RD. Thyrotropin receptor messenger ribonucleic acid is expressed in most brown and white adipose tissue in the Guinea Pig. Endocrinology 1992, 130: 1857–61.
Haraguchi K, Shimura H, Lin L, Saito T, Endo T, Onaya T. Functional expression of thyrotropin receptor in differentiated 3T3-L1 cells: A possible model cell line of extrathyroidal expression of thyrotropin receptor. Biochem Biophys Res Comm 1996, 223: 193–8.
Haraguchi K, Shimura H, Lin L, Endo T, Onaya T. Differentiation of rat preadipocytes is accompanied by expression of thyrotropin receptors. Endocrinology 1996, 137: 3200–5.
Starkey KJ, Janezic A, Jones G, Jordan N, Baker G, Ludgate M. Adipose thyrotropin receptor expression is elevated in graves’ and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo. J Mol Endocrinol 2003, 30: 369–80.
Valyasevi R, Erickson D, Harteneck D, et al. Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor. J Clin Endocrinol Metab 1999, 84: 2557–62.
Marcus C, Erhen H, Bolme P, Armer P. Regulation of lipolysis during the neonatal period importance of thyrotropin. J Clin Invest 1988, 82: 1793–7.
Davies TF, Teng CS, McLachlan SM, Rees Smith B, Hall R. Thyrotropin receptors in adipose tissue, retro-orbital tissue and lymphocytes. Mol Cell Endocrinol 1978, 9: 303–10.
Perros P, Kendall-Taylor P. Demonstration of thyrotropin binding sites in orbital connective tissue: possible role in the pathogenesis of thyroid associated ophthalmopathy. J Endocrinol Invest 1994, 17: 163–70.
Mullin BR, Lee G, Ledley F, Winand R, Kohn L. Thyrotropin interactions with human fat cell membrane preparations and the finding of a soluble thyrotropin binding component. Biochem Biophys Res Comm 1976, 69: 55–62.
Kahaly G, Hansen C, Felke B, Dienes HP. Immunohistochemical staining of retrobulbar adipose-tissue in graves ophthalmopathy. Clin Immunol Immunopathol 1994, 73: 53–62.
Rosen ED, Spiegelman BM. Molecular regulation of adipogenesis. Ann Rev Cell Dev Biol 2000, 16: 145–71
Starkey K, Heufelder A, Baker G, et al. PPARγ in thyroid eye disease: contra-indication for thiazolidenedione use? J Clin Endocrinol Metab 2003, 88: 55–9.
Scherer PE, Williams S, Foglioano M, Baldini G, Lodish HF. A novel serum protein similar to C1q produced exclusively in adipocytes. J Biol Chem 1995, 270: 26746–9.
Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002, 8: 731–7.
Combs T P, Baker GRC, Berg AH, Ludgate ME, Scherer PE. Proptosis in ACRP30 transgenic mice and elevated serum ACRP30 in patients with Graves’ disease and ophthalmopathy: further insight into orbital adipogenesis. Program of the 28th Annual Meeting of the European Thyroid Association, oteborg, Sweden. 2002, p. 32 (abstract).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ludgate, M., Baker, G. Inducing Graves’ ophthalmopathy. J Endocrinol Invest 27, 211–215 (2004). https://doi.org/10.1007/BF03345268
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03345268